Mode
Text Size
Log in / Sign up
Phase 4 Completed N=62 Randomized Quadruple-blind Treatment

Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department

Source: ClinicalTrials.gov NCT02916927 ↗
Enrolled (actual)
62
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcomePrimary: Side Effects — 21; 25 Participants
◆ Published Evidence
Established
21citations · ~3 / year
Slow Infusion of Low-dose Ketamine Reduces Bothersome Side Effects Compared to Intravenous Push: A Double-blind, Double-dummy, Randomized Controlled Trial.
Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2018 · Open access · Likely link

Summary

Objective: The purpose of this study is to determine if administering ketamine as an intravenous (IV) infusion over 15 minutes, as compared to an IV push, will decrease adverse drug reactions without attenuating its analgesic effects. Study design: prospective, randomized, controlled, double-blind trial.

Linked Publications

  • Slow Infusion of Low-dose Ketamine Reduces Bothersome Side Effects Compared to Intravenous Push: A Double-blind, Double-dummy, Randomized Controlled Trial.
    Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2018 · 21 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Side Effects
10; 20; 17; 18; 16; 15
SECONDARY
Side Effects
10; 20; 17; 18; 16; 15
SECONDARY
Side Effect Severity
0.4; 0.6; 0.9; 0.7; .6; 0.7
SECONDARY
How Bothersome Are the Side Effects?
0.1; 0.2; 0.4; 0.3; 0.3; 0.2
SECONDARY
Reduction in Pain on Numeric Rating Scale.
6.5; 2.9; 5.4; 2.8; 4.7; 3.4

Eligibility Criteria

Inclusion Criteria

  • Pain NRS ≥5
  • Anticipated stay in ED ≥1 hour

Exclusion Criteria

  • Pregnant or breast feeding
  • Vital sign abnormalities (SBP 180, HR 150, RR 30, weight 115 kg)
  • Arrhythmias
  • Altered mental status (active psychosis/delirium)
  • Administration of opioid pain medication in previous 1 hour
  • history of acute head or ocular trauma
  • presence of known intracranial mass or vascular lesion
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02916927) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search